TY - JOUR
T1 - Pancreatic islet cell transplantation
T2 - Likely impact on current therapeutics for type 1 diabetes mellitus
AU - Robertson, R. P.
PY - 2001
Y1 - 2001
N2 - Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic pancreatitis who did not have diabetes mellitus was successful in the 1980s, reliable success with alloislet transplantation in patients with diabetes mellitus remained elusive until the year 2000. The reasons for previous failures appear to include use of corticosteroids as an immunosuppressive agent, a drug that both interferes with islet β-cell function and promotes resistance to insulin action. Corticosteroid-free immunosuppressive regimens in one recent series have permitted much greater success for over 1 year. Benefits accrued in this series include normal fasting glucose levels, normal levels of glycosylated haemoglobin, and total independence from exogenous insulin or other therapy for hyperglycaemia. These dramatic results have presented the research community with the challenges of replicating these results and, ultimately, with providing solutions to the serious supply and demand issues that will inevitably follow.
AB - Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic pancreatitis who did not have diabetes mellitus was successful in the 1980s, reliable success with alloislet transplantation in patients with diabetes mellitus remained elusive until the year 2000. The reasons for previous failures appear to include use of corticosteroids as an immunosuppressive agent, a drug that both interferes with islet β-cell function and promotes resistance to insulin action. Corticosteroid-free immunosuppressive regimens in one recent series have permitted much greater success for over 1 year. Benefits accrued in this series include normal fasting glucose levels, normal levels of glycosylated haemoglobin, and total independence from exogenous insulin or other therapy for hyperglycaemia. These dramatic results have presented the research community with the challenges of replicating these results and, ultimately, with providing solutions to the serious supply and demand issues that will inevitably follow.
UR - http://www.scopus.com/inward/record.url?scp=0035208322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035208322&partnerID=8YFLogxK
U2 - 10.2165/00003495-200161140-00001
DO - 10.2165/00003495-200161140-00001
M3 - Review article
C2 - 11735630
AN - SCOPUS:0035208322
SN - 0012-6667
VL - 61
SP - 2017
EP - 2020
JO - Drugs
JF - Drugs
IS - 14
ER -